Tyra Biosciences Cash And Equivalents vs. Cash Per Share
| TYRA Stock | USD 16.18 0.35 2.21% |
For Tyra Biosciences profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Tyra Biosciences to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Tyra Biosciences utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Tyra Biosciences's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Tyra Biosciences over time as well as its relative position and ranking within its peers.
Tyra |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Tyra Biosciences. If investors know Tyra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Tyra Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.61) | Return On Assets (0.20) | Return On Equity (0.29) |
The market value of Tyra Biosciences is measured differently than its book value, which is the value of Tyra that is recorded on the company's balance sheet. Investors also form their own opinion of Tyra Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Tyra Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Tyra Biosciences' market value can be influenced by many factors that don't directly affect Tyra Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Tyra Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Tyra Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Tyra Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Tyra Biosciences Cash Per Share vs. Cash And Equivalents Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Tyra Biosciences's current stock value. Our valuation model uses many indicators to compare Tyra Biosciences value to that of its competitors to determine the firm's financial worth. Tyra Biosciences is currently regarded as top stock in cash and equivalents category among its peers. It is rated second in cash per share category among its peers . The ratio of Cash And Equivalents to Cash Per Share for Tyra Biosciences is about 41,620,272 . At present, Tyra Biosciences' Cash Per Share is projected to slightly grow based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Tyra Biosciences' earnings, one of the primary drivers of an investment's value.Tyra Cash Per Share vs. Cash And Equivalents
Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Tyra Biosciences |
| = | 275.11 M |
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Tyra Biosciences |
| = | 6.61 X |
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
Tyra Cash Per Share Comparison
Tyra Biosciences is currently under evaluation in cash per share category among its peers.
Tyra Biosciences Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Tyra Biosciences, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Tyra Biosciences will eventually generate negative long term returns. The profitability progress is the general direction of Tyra Biosciences' change in net profit over the period of time. It can combine multiple indicators of Tyra Biosciences, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | 381 K | 400.1 K | |
| Net Interest Income | 10.8 M | 11.4 M | |
| Operating Income | -79.9 M | -75.9 M | |
| Net Loss | -69.1 M | -65.7 M | |
| Income Before Tax | -69.1 M | -65.7 M | |
| Total Other Income Expense Net | 10.8 M | 11.4 M | |
| Net Loss | -49.8 M | -47.3 M | |
| Net Loss | -69.1 M | -65.7 M | |
| Income Tax Expense | -3.2 M | -3.1 M | |
| Interest Income | 10.8 M | 11.4 M | |
| Non Operating Income Net Other | 4.1 M | 4.3 M | |
| Change To Netincome | 12.2 M | 12.8 M | |
| Net Loss | (1.62) | (1.70) | |
| Income Quality | 0.73 | 0.64 | |
| Net Income Per E B T | 0.93 | 1.08 |
Tyra Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Tyra Biosciences. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Tyra Biosciences position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Tyra Biosciences' important profitability drivers and their relationship over time.
Use Tyra Biosciences in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Tyra Biosciences position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Tyra Biosciences will appreciate offsetting losses from the drop in the long position's value.Tyra Biosciences Pair Trading
Tyra Biosciences Pair Trading Analysis
The ability to find closely correlated positions to Tyra Biosciences could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Tyra Biosciences when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Tyra Biosciences - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Tyra Biosciences to buy it.
The correlation of Tyra Biosciences is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Tyra Biosciences moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Tyra Biosciences moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Tyra Biosciences can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Tyra Biosciences position
In addition to having Tyra Biosciences in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Compulsion Thematic Idea Now
Compulsion
Companies involved in research, development, and manufacturing of products with compulsion characteristics such as cigarettes, addictive drugs and alcohol. The Compulsion theme has 40 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Compulsion Theme or any other thematic opportunities.
| View All Next | Launch |
Check out World Market Map. For information on how to trade Tyra Stock refer to our How to Trade Tyra Stock guide.You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.
To fully project Tyra Biosciences' future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Tyra Biosciences at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Tyra Biosciences' income statement, its balance sheet, and the statement of cash flows.